Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Gross Margin: 2019-2025

Historic Gross Margin for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to 94.56%.

  • BridgeBio Pharma's Gross Margin rose 1645.00% to 94.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 95.78%, marking a year-over-year decrease of 312.00%. This contributed to the annual value of 98.25% for FY2024, which is 2454.00% up from last year.
  • Per BridgeBio Pharma's latest filing, its Gross Margin stood at 94.56% for Q3 2025, which was down 2.21% from 96.70% recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Gross Margin registered a high of 286.87% during Q4 2021, and its lowest value of -118.64% during Q3 2022.
  • Over the past 3 years, BridgeBio Pharma's median Gross Margin value was 78.11% (recorded in 2024), while the average stood at 80.25%.
  • In the last 5 years, BridgeBio Pharma's Gross Margin crashed by 22,147bps in 2022 and then skyrocketed by 20,402bps in 2023.
  • Over the past 5 years, BridgeBio Pharma's Gross Margin (Quarterly) stood at 286.87% in 2021, then plummeted by 22,147bps to 65.40% in 2022, then surged by 33bps to 65.73% in 2023, then slumped by 116bps to 64.57% in 2024, then soared by 1,645bps to 94.56% in 2025.
  • Its last three reported values are 94.56% in Q3 2025, 96.70% for Q2 2025, and 97.74% during Q1 2025.